Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Asset Utilization Ratio (2021 - 2024)

Allogene Therapeutics' Asset Utilization Ratio history spans 4 years, with the latest figure at 0.0 for Q4 2024.

  • For Q4 2024, Asset Utilization Ratio fell 77.39% year-over-year to 0.0; the TTM value through Dec 2024 reached 0.0, down 77.39%, while the annual FY2024 figure was 0.0, 71.54% down from the prior year.
  • Asset Utilization Ratio for Q4 2024 was 0.0 at Allogene Therapeutics, down from 0.0 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.11 in Q4 2021 and bottomed at 0.0 in Q4 2024.
  • The 4-year median for Asset Utilization Ratio is 0.0 (2022), against an average of 0.03.
  • The largest annual shift saw Asset Utilization Ratio skyrocketed 138.16% in 2022 before it plummeted 99.86% in 2023.
  • A 4-year view of Asset Utilization Ratio shows it stood at 0.11 in 2021, then tumbled by 99.83% to 0.0 in 2022, then decreased by 5.91% to 0.0 in 2023, then tumbled by 77.39% to 0.0 in 2024.
  • Per Business Quant, the three most recent readings for ALLO's Asset Utilization Ratio are 0.0 (Q4 2024), 0.0 (Q3 2024), and 0.0 (Q2 2024).